PMID- 35845404
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220719
IS  - 2296-4185 (Print)
IS  - 2296-4185 (Electronic)
IS  - 2296-4185 (Linking)
VI  - 10
DP  - 2022
TI  - Recent Progress in Bio-Responsive Drug Delivery Systems for Tumor Therapy.
PG  - 916952
LID - 10.3389/fbioe.2022.916952 [doi]
LID - 916952
AB  - Spatially- and/or temporally-controlled drug release has always been the pursuit 
      of drug delivery systems (DDSs) to achieve the ideal therapeutic effect. The 
      abnormal pathophysiological characteristics of the tumor microenvironment, 
      including acidosis, overexpression of special enzymes, hypoxia, and high levels 
      of ROS, GSH, and ATP, offer the possibility for the design of stimulus-responsive 
      DDSs for controlled drug release to realize more efficient drug delivery and 
      anti-tumor activity. With the help of these stimulus signals, responsive DDSs can 
      realize controlled drug release more precisely within the local tumor site and 
      decrease the injected dose and systemic toxicity. This review first describes the 
      major pathophysiological characteristics of the tumor microenvironment, and 
      highlights the recent cutting-edge advances in DDSs responding to the tumor 
      pathophysiological environment for cancer therapy. Finally, the challenges and 
      future directions of bio-responsive DDSs are discussed.
CI  - Copyright (c) 2022 Cong, Chen and Xu.
FAU - Cong, Xiufeng
AU  - Cong X
AD  - Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 
      China.
FAU - Chen, Jun
AU  - Chen J
AD  - Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 
      China.
FAU - Xu, Ran
AU  - Xu R
AD  - Department of Thoracic Surgery, Shengjing Hospital of China Medical University, 
      Shenyang, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220629
PL  - Switzerland
TA  - Front Bioeng Biotechnol
JT  - Frontiers in bioengineering and biotechnology
JID - 101632513
PMC - PMC9277442
OTO - NOTNLM
OT  - bio-responsiveness
OT  - cancer therapy
OT  - drug delivery system
OT  - pathophysiological characteristics
OT  - tumor microenvironment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/07/19 06:00
MHDA- 2022/07/19 06:01
PMCR- 2022/01/01
CRDT- 2022/07/18 03:49
PHST- 2022/04/10 00:00 [received]
PHST- 2022/06/09 00:00 [accepted]
PHST- 2022/07/18 03:49 [entrez]
PHST- 2022/07/19 06:00 [pubmed]
PHST- 2022/07/19 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 916952 [pii]
AID - 10.3389/fbioe.2022.916952 [doi]
PST - epublish
SO  - Front Bioeng Biotechnol. 2022 Jun 29;10:916952. doi: 10.3389/fbioe.2022.916952. 
      eCollection 2022.